Clinical Trial

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 11, 2023 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.
Trial Details
NCT Number NCT05940532
Lead Sponsor Hunan Cancer Hospital
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 41 participants
Start Date 2023-06-14
Primary Completion 2025-01 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-07-11